An FDA orphan drug designation provides several benefits to the sponsor including a seven-year amount of market exclusivity in the United States, if the FDA grant orphan medication exclusivity at acceptance. The FDA offers previously granted orphan drug designation for isavuconazole for the treating invasive aspergillosis and invasive mucormycosis. Related StoriesChildren's Memorial Hermann Medical center offers Halloween protection tipsBoston Kids's and Rock Health synergy to accelerate development of pediatric wellness technologiesStudy: Post medical center syndrome is significant risk element for sufferers undergoing elective surgery Invasive candidiasis is a significant hospital-acquired fungal infection that’s associated with increased morbidity and mortality in certain immunocompromised patients.CBS This Morning Healthwatch New queries about how exactly Texas Ebola affected individual was handled Problems of a potential Ebola outbreak in the U.S. Surface area after an Ebola patient was turned from a Texas medical center originally. Dr. David Agu. The family was confined to their house under armed guard while public-health officials monitor them – part of a rigorous effort to support the deadly disease before it can get a foothold in the usa. Daily monitoring carries a temperature reading twice a time.